Rhumbline Advisers Has $82,000 Stock Position in Upstream Bio, Inc. (NASDAQ:UPB)

Rhumbline Advisers lowered its position in shares of Upstream Bio, Inc. (NASDAQ:UPB) by 20.3% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 13,327 shares of the company’s stock after selling 3,394 shares during the quarter. Rhumbline Advisers’ holdings in Upstream Bio were worth $82,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. Bank of America Corp DE bought a new position in Upstream Bio in the fourth quarter valued at approximately $230,000. Northern Trust Corp acquired a new position in shares of Upstream Bio in the 4th quarter valued at $2,363,000. Legal & General Group Plc bought a new position in shares of Upstream Bio in the 4th quarter worth $28,000. Barclays PLC acquired a new stake in shares of Upstream Bio during the fourth quarter worth $445,000. Finally, MetLife Investment Management LLC acquired a new stake in shares of Upstream Bio during the fourth quarter worth $181,000.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised Upstream Bio from a “sell” rating to a “hold” rating in a research note on Friday, June 6th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $56.50.

Upstream Bio Stock Up 0.5%

Shares of NASDAQ:UPB opened at $10.94 on Friday. The company has a 50 day moving average price of $9.76 and a two-hundred day moving average price of $10.45. Upstream Bio, Inc. has a 52 week low of $5.14 and a 52 week high of $29.46.

Upstream Bio (NASDAQ:UPB) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.02). The firm had revenue of $0.57 million for the quarter, compared to the consensus estimate of $0.71 million. As a group, equities research analysts anticipate that Upstream Bio, Inc. will post -4.3 earnings per share for the current fiscal year.

About Upstream Bio

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.